UK markets close in 5 hours 49 minutes
  • FTSE 100

    +36.21 (+0.51%)
  • FTSE 250

    +214.85 (+0.96%)
  • AIM

    +3.03 (+0.24%)

    +0.0011 (+0.09%)

    +0.0023 (+0.17%)

    -700.84 (-1.70%)
  • CMC Crypto 200

    -0.92 (-0.06%)
  • S&P 500

    +34.03 (+0.82%)
  • DOW

    +318.19 (+0.93%)

    -0.22 (-0.34%)

    +5.20 (+0.29%)
  • NIKKEI 225

    +26.45 (+0.09%)

    -26.81 (-0.09%)
  • DAX

    +153.69 (+1.01%)
  • CAC 40

    +5.24 (+0.08%)

Generic Drugs Market Report 2020-2030

·5-min read

Growth in Leading Regional and National Markets (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.

New York, April 13, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Generic Drugs Market Report 2020-2030" -
A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex)

The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions. The increase in healthcare expenditure and a rise in the cost of pharmaceuticals worldwide results in a strained national budget due to which a high proportion of people are not able to access to essential medications. As per the World Health Organization (WHO), approximately 30% of the world’s population lack access to essential medicines. The main factor that hampers access to these medicines is the cost of these pharmaceutical drugs. The robust growth of the pharmaceutical market and increase in the share of total healthcare spending have reignited the age-old debate on how to balance the cost of innovation in drug research and grant universal access to that research.

Reduction in healthcare expenditure by generic medicines has been acknowledged for a long time. Multiple studies have proven that substituting the brand name drugs with cheaper generic medicines can prove to save about 10-90% of the cost spent on the preparation of these medicines. Government initiatives like reimbursement policies have further encouraged the use of generic drugs and this policy has led the adoption of using generic medicines as a substitute over expensive branded original medications by various healthcare systems.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Market Driving Forces
• Emerging market: This factor has a direct link with the growth of the geographical generic drug market. So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.
• Awareness and advance healthcare systems: Earlier, people, as well as the doctors, were not quite aware of the use of generic drugs but after the introduction of generic drugs, companies and organizations have come up with workshops, conferences and training to promote the idea of generic drugs so that, people could be well-aware of its use.
• Cost-effectiveness and increasing investments: The cost of generic drugs is quite cheap as compared to the brand-name drugs which have increased the sales of generic drugs in the market. As the cost of these drugs is affordable so, many companies have started investing in manufacturing the generic drugs.
• Increase of chronic diseases and the ageing population: This is one of the most important factors that contribute to driving the sales of generic drugs.

How this report will benefit you

In this brand new 431-page report you will receive 66 tables and 287 figures– all unavailable elsewhere.

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Generic Drugs Market by Drug Delivery forecasts from 2020-2030
• Oral
• Dermal/Topical
• Inhalants
• Injectable

• Generic Drugs Market by Distribution Channel forecasts from 2020-2030
• Hospital Pharmacy
• Retail Pharmacy

Generic Drugs Market by Application forecasts from 2020-2030
• Oncology
• Diabetes
• Autoimmune
• Other Application

• Generic Drugs Market forecasts from 2020-2030 by Regional and National Market:
• North America: U.S., Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa
• Latin America: Brazil, Argentina, Mexico, Rest of Latin America

The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions.

• Profiles and generic drugs revenue forecasts from 2020-2030 of these selected leading companies:
• Abbott
• Apotex
• Aspen
• Dr. Reddy’s Laboratories Limited
• Fresenius Kabi
• Mylan
• Novartis
• Pfizer
• Sanofi
• Sun Pharma
• Teva
• Taisho Pharmaceutical Holdings Co Ltd
• ASKA Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Roche Holding

• Qualitative analysis of the generic drugs market:
• SWOT Analysis of the generic drugs market
• Porter’s Five Forces Analysis of the generic drugs market
• Discussion on factors that drive and restrain the generic drugs market

• Key Questions Answered by This Report:
• How is the global market for generic drugs evolving?
• What are the major factors driving and restraining the generic drugs market dynamics?
• What were the market shares of the leading national markets in the global generic drugs market in 2019?
• How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2030?
• How will the market shares for each of the national markets develop from 2020 to 2030?
• Which particular national markets will be the main drivers of growth in the global market for generics from 2020 to 2030?
• How will political and regulatory factors influence the regional markets and submarkets?
• What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2020 and 2030?

This study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001